Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Derazantinib is a powerful inhibitor of FGFR1‒3 kinases and also exhibits activity against the colony stimulating factor-1 receptor (CSF1R) and vascular endothelial growth factor receptor-2 (VEGFR2). This suggests that it may have a unique role in treating patients with intrahepatic cholangiocarcinoma (iCCA). The drug has demonstrated significant clinical efficacy, with durable objective responses, indicating its therapeutic potential for patients with iCCA who have previously been treated and have FGFR2 fusions/rearrangements, mutations, and amplifications. The safety profile of derazantinib is manageable and compares favorably to other FGFR inhibitors, particularly due to its low incidence of drug-related side effects such as hand-foot syndrome, stomatitis, and retinal and nail toxicity. These results highl…